Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7,555 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The German S3 guideline prostate cancer: aspects for the radiation oncologist.
Wenz F, Martin T, Böhmer D, Martens S, Sedlmayer F, Wirth M, Miller K, Heidenreich A, Schrader M, Hinkelbein W, Wiegel T. Wenz F, et al. Among authors: miller k. Strahlenther Onkol. 2010 Oct;186(10):531-4. doi: 10.1007/s00066-010-2193-3. Epub 2010 Sep 30. Strahlenther Onkol. 2010. PMID: 20890742
Dose escalation for patients with decreasing PSA during radiotherapy for elevated PSA after radical prostatectomy improves biochemical progression-free survival: results of a retrospective study.
Siegmann A, Bottke D, Faehndrich J, Lohm G, Miller K, Bartkowiak D, Wiegel T, Hinkelbein W. Siegmann A, et al. Among authors: miller k. Strahlenther Onkol. 2011 Aug;187(8):467-72. doi: 10.1007/s00066-011-2229-3. Epub 2011 Jul 22. Strahlenther Onkol. 2011. PMID: 21786112
Radiotherapy and Hormone Treatment in Prostate Cancer.
Böhmer D, Wirth M, Miller K, Budach V, Heidenreich A, Wiegel T. Böhmer D, et al. Among authors: miller k. Dtsch Arztebl Int. 2016 Apr 8;113(14):235-41. doi: 10.3238/arztebl.2016.0235. Dtsch Arztebl Int. 2016. PMID: 27146591 Free PMC article. Review.
Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.
Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, Störkel S, Willich N, Semjonow A, Souchon R, Stöckle M, Rübe C, Weissbach L, Althaus P, Rebmann U, Kälble T, Feldmann HJ, Wirth M, Hinke A, Hinkelbein W, Miller K. Wiegel T, et al. Among authors: miller k. J Clin Oncol. 2009 Jun 20;27(18):2924-30. doi: 10.1200/JCO.2008.18.9563. Epub 2009 May 11. J Clin Oncol. 2009. PMID: 19433689 Clinical Trial.
Salvage radiotherapy after prostatectomy - what is the best time to treat?
Siegmann A, Bottke D, Faehndrich J, Brachert M, Lohm G, Miller K, Bartkowiak D, Hinkelbein W, Wiegel T. Siegmann A, et al. Among authors: miller k. Radiother Oncol. 2012 May;103(2):239-43. doi: 10.1016/j.radonc.2011.10.024. Epub 2011 Nov 25. Radiother Oncol. 2012. PMID: 22119375
Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome--results of a retrospective study.
Wiegel T, Lohm G, Bottke D, Höcht S, Miller K, Siegmann A, Schostak M, Neumann K, Hinkelbein W. Wiegel T, et al. Among authors: miller k. Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1009-16. doi: 10.1016/j.ijrobp.2008.06.1922. Epub 2008 Oct 27. Int J Radiat Oncol Biol Phys. 2009. PMID: 18963539
7,555 results